Skip to content

Clinical effect of EEG biomimetic electrical stimulation combined with vestibular rehabilitation on persistent postural-perceptual dizziness

Clinical effect of EEG biomimetic electrical stimulation combined with vestibular rehabilitation on persistent postural-perceptual dizziness

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096864
Enrollment
Unknown
Registered
2025-02-07
Start date
2023-05-02
Completion date
Unknown
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Postural-Perceptual Dizziness

Interventions

Control group:Oral escitalopram
rehabilitation group:Oral escitalopram+vestibular rehabilitation training
electrical stimulation group:Oral escitalopram+EEG biomimetic electrical stimulation treatment
combined group:Oral escitalopram+vestibular rehabilitation training+EEG biomimetic electrical stimulation treatment

Sponsors

Wuhan Puren Hospital Affiliated to Wuhan University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for PPPD established by the Barany Association Committee for the International Classification of Vestibular Diseases ; (2) Age 30-75 years old; (3) Patients with normal vestibular examination or no special diagnostic significance; (4) Patients who can accept and cooperate with relevant assessment and treatment interventions; (5) Patients who are informed of the treatment plan and have signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with contraindications of EEG bionic electrical stimulation technology, such as patients with bleeding tendencies such as coagulation dysfunction and acute cerebral hemorrhage; Patients with severe heart disease or pacemakers; Patients with a history of craniocerebral surgery, intracranial infection, craniocerebral tumor or intracranial vascular metal stent implantation; Patients with epilepsy; (2) Patients with serious heart, brain, liver, kidney and other organic diseases and systemic diseases; (3) Drug and alcohol abusers; (4) pregnant patients; (5) Patients who have had other exercise treatment plans in the past or recent 1 month.

Design outcomes

Primary

MeasureTime frame
Dizziness handicap inventory;Visual analogue scale;

Secondary

MeasureTime frame
Mean center of gravity velocity;Mean center of gravity amplitude;Activities-specific balance confidence;Self-rating anxiety scale;Self-rating depression scale;Sleep structure;Pittsburgh sleep quality index scale;Clinical efficacy evaluation;Dizziness frequency;Dizziness duration;Factors affecting the recurrence of dizziness;Factors affecting clinical efficacy;

Countries

China

Contacts

Public ContactGangLi Yan

Wuhan Puren Hospital Affiliated to Wuhan University of Science and Technology

252597520@qq.com+86 139 9553 3909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026